Global Pharmerging Market Size Study by Product Type (Pharmaceuticals, Healthcare), by Indication (Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, Others), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, E-commerce

Global Pharmerging Market Size Study by Product Type (Pharmaceuticals, Healthcare), by Indication (Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, Others), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, E-commerce, Drug Stores), and Regional Forecasts 2022-2032

The Global Pharmerging Market is valued at approximately USD 2.34 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.6% over the forecast period 2024-2032. Pharmerging"" is a term used to describe pharmaceutical markets in emerging economies that are experiencing rapid growth. These markets typically include countries with developing economies that are investing heavily in healthcare infrastructure and expanding access to medicines and healthcare services. Pharmerging markets often exhibit high growth potential due to factors such as increasing population, rising incomes, greater healthcare spending, and expanding access to health insurance. Regulatory bodies in these regions are also facilitating the approval process for generic medications, enhancing market accessibility.

The rise in the incidence of chronic diseases necessitates comprehensive insurance coverage and affordable medication options. Insurance companies in pharmerging countries are offering policies to reduce patient costs, further driving market growth. Additionally, the heightened awareness of the importance of early disease detection is contributing to market expansion. Companies are increasingly producing generic medicines in larger quantities to reach underprivileged populations in developing economies, which is crucial for market growth. Asia Pacific, particularly China and Japan, is expected to lead this growth, driven by substantial advancements in the pharmaceuticals sector. However, IP protection issues and regulatory compliance and approval processes are some factors hampering the market growth.

The pharmerging market's landscape is also shaped by the healthcare systems in these countries, which are promoting generic medications to reduce costs. This shift is accompanied by collaborations between private and public sectors to raise awareness about the benefits of generic therapies. Generic drugs, being more affordable due to lower marketing and advertising costs, are increasingly being adopted. Governments are launching initiatives like India's 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana' to promote generic medicines and make them accessible to most of the population. Furthermore, the increasing prevalence of chronic diseases necessitates early detection and timely treatment, boosting the demand for affordable medications and thus augmenting the pharmerging market.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and Middle East and Africa. In 2023, Asia Pacific dominated the market, driven by significant investments in R&D, rising prevalence of chronic diseases, and urbanization. The market in North America is also expected to grow due to technological advancements in healthcare facilities. The growing demand for premium healthcare products in North America contributing to the market expansion leading to fastest growing region. The region's increasing aerospace and industrial activities support the demand for several tool storage products.

Major market players included in this report are:

Abbott Laboratories

Koninklijke Philips N.V.

F. Hoffmann-La Roche Ltd.

Merck & Co., Inc.

Novartis AG

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

AstraZeneca

GlaxoSmithKline plc

Lupin

Tata Consultancy Services Ltd.

Sun Pharmaceutical Industries Ltd.

Huadong Medicine Co., Ltd.

Eurofarma Laboratórios S.A.

OAO Pharmstandard

The detailed segments and sub-segment of the market are explained below:

By Product Type:

Pharmaceuticals

Healthcare

By Indication:

Lifestyle Diseases

Cancer and Autoimmune Diseases

Infectious Diseases

Others

By Distribution Channel:

Hospitals

Clinics

Retail Pharmacies

E-commerce

Drug Stores

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.